tradingkey.logo

Hims & Hers slides after it forecasts Q1 revenue below estimates

ReutersFeb 24, 2026 9:44 AM

Shares of online telehealth company Hims & Hers Health HIMS.N fall 6.7% to $15.51 in premarket trading

Co on Monday forecast Q1 revenue below estimates, citing a $65 million hit from changes in the shipping of weight-loss products for personalized prescriptions

HIMS, which grew rapidly after it offered cheaper compounds of weight-loss drugs, now expects Q1 revenue in the range of $600 million to $625 million, below estimates of $653.11 million, according to data compiled by LSEG

Morningstar sees several uncertainties for HIMS, including the Novo Nordisk litigation, regulatory risks around compounding, and execution risk for new launches and markets

Earlier this month, the FDA said it would take action against HIMS for its $49 copycat weight-loss pill; co was also referred to the Dept of Justice for violation

16 analysts rate the stock "hold" on average; median PT is $22 - data compiled by LSEG

As of last close, stock down 52.23% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI